Teva Pharmaceutical Industries Limited American Depositary Shares - TEVA STOCK NEWS

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Auspex Pharmaceuticals have settled a patent dispute with Aurobindo concerning Aurobindo's ANDA for a generic version of Teva's AUSTEDO (deutetrabenazine). The agreement ends the litigation in the U.S. District Court for New Jersey, allowing Aurobindo to sell its generic product starting in April 2033 or earlier under specific conditions. Teva asserts the agreement underscores the strength of its intellectual property for AUSTEDO, which treats chorea associated with Huntington's disease and tardive dyskinesia.

Teva Pharmaceuticals has released results from a retrospective U.S. study demonstrating the effectiveness of AJOVY (fremanezumab-vfrm) in reducing monthly migraine days when used with gepants for acute treatment. At study initiation, patients averaged 15.8 monthly migraine days, which decreased by 6.5 days (41.1% reduction) post-treatment. This data, presented at the 2022 AHS Annual Meeting, highlights AJOVY's potential in managing migraines across diverse patient populations. However, 9.1% of patients reported adverse events, including injection site reactions and uveitis.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced eight abstracts on the use of AJOVY (fremanezumab-vfrm) for migraine treatment at the 2022 American Headache Society Annual Meeting in Denver, June 9-12. Key presentations include a late-breaking study on AJOVY's effectiveness with gepants for acute treatment and subgroup analysis from the Phase 3b FOCUS study. The findings aim to highlight AJOVY's impact on patients with specific migraine treatment needs, particularly during Migraine Awareness Month.

STADA is launching Hukyndra®, a high-concentration, citrate-free biosimilar to adalimumab, in select European markets including France, Germany, Finland, and Sweden. This launch follows approval from the European Commission and represents the first product from STADA's partnership with Alvotech. Hukyndra® is designed to enhance patient comfort with reduced injection-site pain. The biosimilar is approved for treating various inflammatory conditions, supporting patient access to vital therapies in Europe.

Teva Pharmaceuticals, in partnership with Direct Relief and the National Association of Free and Charitable Clinics, has launched a $2 million program to enhance access to mental health care for underserved populations. The initiative will provide funding over two years to free clinics while donating generic medications for anxiety and depression. Initially focused on Florida, New Jersey, and California, this program aims to address health equity issues exacerbated by the COVID-19 pandemic, supporting clinics to provide necessary resources and care for uninsured patients.

Teva Pharmaceuticals has settled opioid-related claims with the Attorney General of West Virginia, agreeing to pay $75 million over 15 years and provide $27 million in the generic version of Narcan over 10 years. The settlement also includes $8 million for attorney fees. While this settlement advances efforts to address opioid addiction, it is not an admission of liability. Teva is negotiating a national settlement to further address ongoing litigation.

Teva Pharmaceuticals has released new data highlighting the efficacy and safety of AUSTEDO in postmenopausal women with tardive dyskinesia (TD) over a three-year open-label extension study. AUSTEDO showed significant improvements in motor symptoms, with 68% of patients experiencing notable improvements by Week 145. Additionally, the psychological, social, and physical impacts of TD were examined through surveys of patients and caregivers, revealing considerable negative effects on daily life. These findings will be presented at the 2022 American Psychiatric Association Annual Meeting in New Orleans.

Teva Pharmaceutical has received approval from the UK Medicines & Healthcare Regulatory Agency (MHRA) for its biosimilar Ongavia^® (ranibizumab), targeting wet age-related macular degeneration (AMD) and other eye diseases. Ongavia^® is the first ophthalmology biosimilar to be commercialized by Teva in Europe. The approval allows treatment for visual impairment-related conditions, potentially enhancing patient access to affordable therapies. Teva's partnership with Bioeq AG aims to extend Ongavia^®'s commercialization throughout Europe.

Teva Pharmaceuticals announced four data presentations regarding AUSTEDO (deutetrabenazine) and TV-46000, presented at the American Psychiatric Association Annual Meeting from May 21-25, 2022. Key studies include long-term safety and efficacy of AUSTEDO for tardive dyskinesia, and a new copolymer technology for TV-46000 targeting schizophrenia. Teva will also host educational sessions on mental health's social determinants and the clinical benefits of long-acting injectables in schizophrenia treatment. The data reflects Teva's commitment to addressing mental health needs.